

# IMPROVING THE TRANSDUCTION EFFICIENCY OF AN AEROSOL-DELIVERED LENTIVIRAL VECTOR FOR CYSTIC FIBROSIS GENE THERAPY

Harshavardini Padmanabhan<sup>1,2</sup>, Patricia Cmielewski<sup>1,2,3</sup>

<sup>1</sup>Department of Respiratory and Sleep Medicine, South CF Research Laboratory, Women's & Children's Hospital, Adelaide, South Australia  
<sup>2</sup>School of Paediatrics and Reproductive Health and Robinson Research Institute, The University of Adelaide, South Australia

## BACKGROUND:

Gene therapy is a potential treatment for cystic fibrosis (CF) lung disease, whereby the therapeutic gene is delivered to the lung to produce functional **CFTR**. Aerosol delivery of a gene vector to the lung is an ideal treatment approach because it is non-invasive, easy to administer and less cumbersome compared to liquid delivery.

It is thought that the virus particles are subjected to destructive surface tension and shear stress effects during aerosolization (1). We have utilised a vibrating mesh nebuliser (Aeroneb<sup>®</sup>Pro) (Figure 1) for *in-vitro* studies as it is thought to produce minimal shear stress on our lentiviral (LV) gene transfer vector carrying the reporter gene.


The aim of this study was:

- 1) To test a range of protective agents in which the LV-LacZ is suspended to improve the viability of the LV and in turn gene transduction.
- 2) To study the distribution pattern of gene expression using liquid delivery vs aerosol delivery of LV-LacZ in *in-vitro* and *ex-vivo* experiments.




Figure 1: Aeroneb<sup>®</sup>Pro used to aerosolize LV-LacZ

## METHODS:



## RESULTS:

- The transduction obtained via aerosol was 33% to 51% of the number of cells compared to liquid control, for 1:25 to 1:100 dilutions of the LV-LacZ (Figure 2).



- Virus suspended in FreeStyle<sup>™</sup> medium showed significantly higher levels of transduction (58%) when compared to other diluents (Figure 3).

- Delivery of LV-LacZ aerosol of different VMD (3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, 12.0, 13.0, 14.0, 15.0, 16.0, 17.0, 18.0, 19.0, 20.0, 21.0, 22.0, 23.0, 24.0, 25.0, 26.0, 27.0, 28.0, 29.0, 30.0, 31.0, 32.0, 33.0, 34.0, 35.0, 36.0, 37.0, 38.0, 39.0, 40.0, 41.0, 42.0, 43.0, 44.0, 45.0, 46.0, 47.0, 48.0, 49.0, 50.0, 51.0, 52.0, 53.0, 54.0, 55.0, 56.0, 57.0, 58.0, 59.0, 60.0, 61.0, 62.0, 63.0, 64.0, 65.0, 66.0, 67.0, 68.0, 69.0, 70.0, 71.0, 72.0, 73.0, 74.0, 75.0, 76.0, 77.0, 78.0, 79.0, 80.0, 81.0, 82.0, 83.0, 84.0, 85.0, 86.0, 87.0, 88.0, 89.0, 90.0, 91.0, 92.0, 93.0, 94.0, 95.0, 96.0, 97.0, 98.0, 99.0, 100.0) showed no statistically significant difference in gene expression (Figure 4).

- In-vitro* tests showed that a non-uniform distribution of the gene expression was produced by lentiviral vector aerosol (Figure 4a) compared to the more discreet clusters (arrows, Figure 4b) observed after liquid bolus vector delivery.

- Ex-vivo* mouse trachea was transduced by LV-LacZ aerosols, with a more uniform distribution of gene expression along the trachea, observed (arrows on Figure 4c) compared to the patchy distribution normally observed *in-vivo* (not shown).

- In liquid bolus delivery, gene expression was observed in a discrete region of the trachea (arrows on Figure 4d).




Figure 4: First data (n=1) of planned LV-LacZ aerosol for mouse in CHO-K1 cells by (a) aerosol (b) liquid bolus delivery. First data (n=1) of planned LV-LacZ aerosol for mouse trachea by (c) aerosol (d) liquid bolus delivery

## CONCLUSION:

We showed that LV-LacZ aerosol was able to transduce about 33% to 51% of cells.

Scholarship by CF Australia. We thank Nigel Farrow and Chantelle Minton for their assistance with this project.

- We speculate that the presence of FreeStyle<sup>™</sup> media aids in protecting the LV from shear stress compared to other diluents.
- Ex-vivo* transduction of mouse trachea via LV-aerosol showed a well distributed uniform distribution of gene expression along the length of the trachea.
- To improve the levels of gene transduction we plan to test different nebulization platforms.
- These findings assist in our understanding of LV aerosolization characteristics and provide practical information for future testing into the lungs of animal models and ultimately for CF airway disease.

## ACKNOWLEDGEMENTS:

Experimental Feeding: MCH Foundation and Curious Foundation. Environmental Pathways: CF Australia. Statistical analysis: Dr. Nigel Farrow.



## REFERENCES:

1. Yang W, Marr LC. Mechanisms by Which Ambient Humidity May Affect Viruses in Aerosols. Appl Environ Microb. 2012;78(19):6781-8.